文献速递冠心病

短暂性ST段抬高型心肌梗死血运重建时机:一项随机临床试验

Timing of revascularization in patients with transient ST-segment elevation myocardial infarction: a randomized clinical trial.
PubMed 文献 · Eur Heart J · 2019-01-01

本研究为随机临床试验,纳入142例短暂性STEMI患者,对比立即(STEMI样,中位0.3小时)与延迟(NSTEMI样,中位22.7小时)侵入策略对CMR测量的梗死面积的影响。结果显示两组梗死面积均较小且无差异(1.3% vs 1.5%,P=0.48),30天MACE也无差异(2.9% vs 2.8%,P=1.00)。但延迟组有4例(5.6%)在等待造影期间因再梗死症状需紧急干预。

要点

  • 短暂性STEMI患者立即与延迟侵入策略的梗死面积无显著差异
  • 两组30天MACE发生率低且无差异
  • 延迟策略组有5.6%患者等待期间需紧急干预

核心结论

  • 短暂性STEMI的梗死面积总体较小,且不受立即或延迟侵入策略影响
  • 短期MACE低且两组无差异,但延迟组有额外患者需紧急干预

研究设计与样本

  • 随机临床试验,纳入142例短暂性STEMI患者,随机分为立即侵入组(中位0.3小时,IQR 0.2-0.7)和延迟侵入组(中位22.7小时,IQR 18.2-27.3)

主要发现

  • 第4天CMR测量的梗死面积占左心室心肌质量百分比:立即组1.3%(IQR 0.0-3.5%),延迟组1.5%(IQR 0.0-4.1%),P=0.48
  • 30天MACE(死亡、再梗死或靶血管血运重建)发生率:立即组2.9%,延迟组2.8%,P=1.00
  • 延迟组有4例额外患者(5.6%)在等待造影期间因再梗死症状和体征需紧急干预

临床怎么用

  • 对于短暂性STEMI患者,立即或延迟侵入策略均可考虑,梗死面积和短期预后相似
  • 延迟策略需警惕等待期间再梗死风险,本研究中延迟组5.6%需紧急干预

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Patients with acute coronary syndrome who present initially with ST-elevation on the electrocardiogram but, subsequently, show complete normalization of the ST-segment and relief of symptoms before reperfusion therapy are referred to as transient ST-segment elevation myocardial infarction (STEMI) and pose a therapeutic challenge. It is unclear what the optimal timing of revascularization is for these patients and whether they should be treated with a STEMI-like or a non-ST-segment elevation myocardial infarction (NSTEMI)-like invasive approach. The aim of the study is to determine the effect of an immediate vs. a delayed invasive strategy on infarct size measured by cardiac magnetic resonance imaging (CMR). METHODS AND RESULTS: In a randomized clinical trial, 142 patients with transient STEMI with symptoms of any duration were randomized to an immediate (STEMI-like) [0.3 h; interquartile range (IQR) 0.2-0.7 h] or a delayed (NSTEMI-like) invasive strategy (22.7 h; IQR 18.2-27.3 h). Infarct size as percentage of the left ventricular myocardial mass measured by CMR at day four was generally small and not different between the immediate and the delayed invasive group (1.3%; IQR 0.0-3.5% vs. 1.5% IQR 0.0-4.1%, P = 0.48). By intention to treat, there was no difference in major adverse cardiac events (MACE), defined as death, reinfarction, or target vessel revascularization at 30 days (2.9% vs. 2.8%, P = 1.00). However, four additional patients (5.6%) in the delayed invasive strategy required urgent intervention due to signs and symptoms of reinfarction while awaiting angiography. CONCLUSION: Overall, infarct size in transient STEMI is small and is not influenced by an immediate or delayed invasive strategy. In addition, short-term MACE was low and not different between the treatment groups.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Lemkes JS, Janssens GN, van der Hoeven NW, et al. Timing of revascularization in patients with transient ST-segment elevation myocardial infarction: a randomized clinical trial. Eur Heart J. 2019. PMID: 30371767. doi:10.1093/eurheartj/ehy651

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。